Ambagon Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
2ndary - Private
- Investors
-
11
Ambagon Therapeutics General Information
Description
Developer of small-molecule cancer drugs designed to stabilize the direct interaction of oncogenic proteins. The company's drugs selectively augment the endogenous tumor suppression activity of proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches, enabling physicians to have opportunities to address other major unmet clinical needs.
Contact Information
Website
www.ambagontx.comCorporate Office
- De Lismortel 31
- 5612 AR Eindhoven
- Netherlands
Corporate Office
- De Lismortel 31
- 5612 AR Eindhoven
- Netherlands
Ambagon Therapeutics Timeline
Ambagon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 28-Feb-2022 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A) | 05-Jan-2022 | Completed | Product Development | |||
| 3. Seed Round | 17-Jul-2020 | Completed | Startup | |||
| 2. Grant | 28-Jun-2019 | $28.2K | Completed | Startup | ||
| 1. Accelerator/Incubator | 01-Apr-2019 | $32.9K | Completed | Startup |
Ambagon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
Ambagon Therapeutics Comparisons
Industry
Financing
Details
Ambagon Therapeutics Competitors (92)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunOs Therapeutics | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Plexium | Venture Capital-Backed | San Diego, CA | ||||
| Accuronix Therapeutics | Venture Capital-Backed | Saint Louis, MO | ||||
| Tvardi Therapeutics | Venture Capital-Backed | Sugar Land, TX | ||||
| Cullgen | Venture Capital-Backed | San Diego, CA |
Ambagon Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ambagon Therapeutics Patents
Ambagon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240174708-A1 | Compounds for targeted protein degradation | Pending | 03-Oct-2022 |
Ambagon Therapeutics Executive Team (14)
| Name | Title | Board Seat |
|---|---|---|
| Christian Ottmann Ph.D | Co-Founder & Chief Executive Officer | |
| Lucas Brunsveld Ph.D | Co-Founder & Member of Scientific Advisory Board | |
| Thomas Marty | Vice President of Finance | |
| Michelle Arkin Ph.D | Co-Founder, Member of Scientific Advisory Board & Board Member | |
| Alan Ashworth Ph.D | Member of Scientific Advisory Board |
Ambagon Therapeutics Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam Rosenberg JD | Self | Chairman | |
| Christian Schubert Ph.D | AbbVie Ventures | Board Member | |
| Ivan Burkov Ph.D | Inkef | Board Member | |
| Janwillem Naesens | Droia Ventures | Board Member | |
| Melissa McCracken Ph.D | Nextech Invest | Board Member |
Ambagon Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ambagon Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Nextech Invest | Venture Capital | Minority | ||
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Blackwell Partners | Asset Manager | Minority | ||
| Droia Ventures | Venture Capital | Minority |
Ambagon Therapeutics FAQs
-
When was Ambagon Therapeutics founded?
Ambagon Therapeutics was founded in 2019.
-
Who is the founder of Ambagon Therapeutics?
Christian Ottmann Ph.D, Lucas Brunsveld Ph.D, Michelle Arkin, and Michelle Arkin Ph.D are the founders of Ambagon Therapeutics.
-
Who is the CEO of Ambagon Therapeutics?
Christian Ottmann Ph.D is the CEO of Ambagon Therapeutics.
-
Where is Ambagon Therapeutics headquartered?
Ambagon Therapeutics is headquartered in Eindhoven, Netherlands.
-
What is the size of Ambagon Therapeutics?
Ambagon Therapeutics has 36 total employees.
-
What industry is Ambagon Therapeutics in?
Ambagon Therapeutics’s primary industry is Drug Discovery.
-
Is Ambagon Therapeutics a private or public company?
Ambagon Therapeutics is a Private company.
-
What is Ambagon Therapeutics’s current revenue?
The current revenue for Ambagon Therapeutics is .
-
How much funding has Ambagon Therapeutics raised over time?
Ambagon Therapeutics has raised $103M.
-
Who are Ambagon Therapeutics’s investors?
Citadel Enterprise Americas, Nextech Invest, AbbVie Ventures, Blackwell Partners, and Droia Ventures are 5 of 11 investors who have invested in Ambagon Therapeutics.
-
Who are Ambagon Therapeutics’s competitors?
ImmunOs Therapeutics, Plexium, Accuronix Therapeutics, Tvardi Therapeutics, and Cullgen are some of the 92 competitors of Ambagon Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
